Answers are grounded in this paper and cite their sources.
Systemic sclerosis (SSc) is a rare multisystem autoimmune disease characterized by vasculopathy, immune dysregulation, and progressive fibrosis. Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is a common complication of SSc. Dupilumab, a humanized monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα), suppresses the IL-4/IL-13 signaling as well as type 2 inflammatory responses. This study aimed to evaluate the anti-inflammatory and antifibrotic effects of anti-IL-4Rα antibody in SSc-ILD and to elucidate its underlying mechanisms. An in vitro model of THP-1 cells was established to evaluate the effects of dupilumab on the profibrotic phenotypic transition of macrophages. Concurrently, a hypochlorous acid (HOCl)-induced SSc-ILD mouse model was established to assess the in vivo efficacy of anti-IL-4Rα antibody and explore possible mechanism. In vitro, dupilumab suppressed IL-4/IL-13-induced profibrotic differentiation of macrophages. In vivo, IL-4/IL-13 blockade improved pulmonary function and radiographic outcomes, mitigated fibrosis and collagen deposition in the lungs and skin, reduced inflammatory cytokines levels in bronchoalveolar lavage fluid (BALF) and serum, and downregulated the expression of proinflammatory and profibrotic factors in the lungs and BALF. Mechanistically, anti-IL-4Rα antibody inhibited the activation of TGF-β1/Smad and JAK/STAT signaling pathways in lung tissue. Anti-IL-4Rα antibody attenuated HOCl-induced pulmonary inflammation and fibrosis in mice. These therapeutic effects may be mediated by suppressing the activation of the TGF-β1-Smad and JAK-STAT signaling. These findings support dupilumab as a promising therapeutic candidate for SSc-ILD patients. Not applicable
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: